Atossa Therapeutics received positive feedback from the FDA regarding its drug candidate, (Z)-Endoxifen.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Atossa Therapeutics received positive feedback from the FDA regarding its drug candidate, (Z)-Endoxifen.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA provided positive feedback on Atossa Therapeutics' drug (Z)-Endoxifen.1 source
Positive feedback from the FDA advances Atossa Therapeutics' IND submission.1 source
Keep exploring
The entities involved
-
Atossa Therapeutics (United States)
company in Seattle, United States
Nothing else this week.
- FDA
Related events
- A product was launched in the U.S. market following FDA involvement.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- Matthew Zorn, Deputy General Counsel at the U.S. Dept., discussed issues around FDA review, concurrent with Marcus and Amber establishing VETS.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
Coverage
Newest first; wire copies grouped- PR NewswireAtossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic
- PR NewswireAtossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therape